Сравнение

Cetrorelix vs. Icatibant

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

120287-85-6

138614-30-9

Молекулярная масса

1431.06 g/mol

1304.52 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Cetrorelix

Cetrorelix competitively and immediately blocks the pituitary GnRH receptor, rapidly suppressing LH and FSH release — without the initial hormone surge ('flare') of GnRH agonists.

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Cetrorelix	Icatibant
Германия	Рецептурный	Рецептурный
США	Рецептурный	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Cetrorelix and Icatibant?: Cetrorelix is classified as "Исследования (прочее)", while Icatibant is classified as "Исследования (прочее)". Cetrorelix: Cetrorelix is a synthetic decapeptide and GnRH antagonist. It is used in assisted reproduction (IVF) to prevent a premature LH surge during controlled ovarian stimulation. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Cetrorelix or Icatibant?: The highest available evidence level is "РКИ на людях" for Cetrorelix and "РКИ на людях" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Cetrorelix and Icatibant in Germany and the United States?: Германия: Cetrorelix — Рецептурный, Icatibant — Рецептурный. США: Cetrorelix — Рецептурный, Icatibant — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Cetrorelix

Icatibant

Германия

Рецептурный

США

Рецептурный

Frequently asked questions

What is the difference between Cetrorelix and Icatibant?

Cetrorelix is classified as "Исследования (прочее)", while Icatibant is classified as "Исследования (прочее)". Cetrorelix: Cetrorelix is a synthetic decapeptide and GnRH antagonist. It is used in assisted reproduction (IVF) to prevent a premature LH surge during controlled ovarian stimulation. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Cetrorelix or Icatibant?

The highest available evidence level is "РКИ на людях" for Cetrorelix and "РКИ на людях" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Cetrorelix and Icatibant in Germany and the United States?

Германия: Cetrorelix — Рецептурный, Icatibant — Рецептурный. США: Cetrorelix — Рецептурный, Icatibant — Рецептурный. These are factual summaries with source and review date on the individual pages.